The U.S. Food and Drug Administration (FDA) has rejected the approval of Summit Therapeutics' lung cancer drug, ivonescimab. This decision follows a clinical trial that reportedly failed to achieve its primary survival endpoint.
The drug, which was invented in China, was closely watched within the biotech sector. Its rejection by the FDA is seen as a setback for Beijing's burgeoning biotechnology industry and delays the introduction of the PD-1xVEGF drug class in the United States.
Summit's ivonescimab was denied approval for a specific lung cancer setting. This is a developing story and will be updated as details emerge.